Applying Design for Manufacturability (DFM) Concept to World’s First Intranasal Neurostimulating Device Flex partnered with Allergan to produce TrueTear ® , a state-of-the-art technology. From Pilot to Clinical Build The program originated with an engagement from Oculeve to work on the disposable portion, pilot and clinical build. As Flex developed a relationship built on trust, Oculeve awarded the durable, then commercial activities to the company. When Allergan acquired Oculeve, the strong partnership with Flex, combined with continued communication, team commitment and sense of urgency enabled a smooth transition that didn’t affect the journey to market. After receiving FDA clearance in April 2017, TrueTear ® was introduced to ophthalmologists and is now being produced in Fle

Join for free to read